MA32931B1 - Compositions antimicrobiennes - Google Patents

Compositions antimicrobiennes

Info

Publication number
MA32931B1
MA32931B1 MA33932A MA33932A MA32931B1 MA 32931 B1 MA32931 B1 MA 32931B1 MA 33932 A MA33932 A MA 33932A MA 33932 A MA33932 A MA 33932A MA 32931 B1 MA32931 B1 MA 32931B1
Authority
MA
Morocco
Prior art keywords
compositions
antimicrobial compositions
antimicrobial
tolerability
infection
Prior art date
Application number
MA33932A
Other languages
Arabic (ar)
English (en)
Inventor
Danping Li
Eric S Burak
David S Dresback
Danielle Beurer Lord
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32931(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Publication of MA32931B1 publication Critical patent/MA32931B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne des compositions antimicrobiennes, et plus particulièrement des compositions de dérivés d'acides quinolone-carboxyliques. Ces compositions présentent une solubilité, une stabilité et une tolérabilité améliorées, et sont utiles en administration intraveineuse pour le traitement, la prévention ou la réduction du risque d'infection.
MA33932A 2008-11-15 2009-11-12 Compositions antimicrobiennes MA32931B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19925308P 2008-11-15 2008-11-15
PCT/US2009/064220 WO2010056872A2 (fr) 2008-11-15 2009-11-12 Compositions antimicrobiennes

Publications (1)

Publication Number Publication Date
MA32931B1 true MA32931B1 (fr) 2012-01-02

Family

ID=42170697

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33932A MA32931B1 (fr) 2008-11-15 2009-11-12 Compositions antimicrobiennes

Country Status (23)

Country Link
US (5) US20120065186A1 (fr)
EP (1) EP2373166A4 (fr)
JP (3) JP6063123B2 (fr)
KR (1) KR101767689B1 (fr)
CN (3) CN103705942B (fr)
AU (1) AU2009314072C1 (fr)
BR (2) BRPI0921705B8 (fr)
CA (1) CA2743419C (fr)
CO (1) CO6382082A2 (fr)
CR (1) CR20110320A (fr)
EA (1) EA025637B1 (fr)
EC (1) ECSP11011119A (fr)
IL (1) IL212781A (fr)
MA (1) MA32931B1 (fr)
MX (1) MX2011005117A (fr)
MY (3) MY188453A (fr)
NI (1) NI201100097A (fr)
NZ (1) NZ593345A (fr)
PE (2) PE20160116A1 (fr)
SV (1) SV2011003907A (fr)
UA (1) UA102709C2 (fr)
WO (1) WO2010056872A2 (fr)
ZA (1) ZA201104108B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373166A4 (fr) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc Compositions antimicrobiennes
HRP20200567T1 (hr) 2011-11-29 2020-06-26 Jurox Pty Ltd Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon
JP6395200B2 (ja) * 2012-10-22 2018-09-26 ジェクス株式会社 ケイ素含有化合物水溶液及び該水溶液を含む抗菌・抗ウィルス剤
AU2014225392A1 (en) * 2013-03-08 2015-09-24 Melinta Therapeutics, Inc. Crystalline forms of D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate
EP2969004B1 (fr) 2013-03-15 2026-02-25 Melinta Subsidiary Corp. Delafloxacine et son utilisation dans le traitement d'infections chez des patients obèses
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
CA3016809C (fr) 2016-03-14 2024-03-12 Santen Pharmaceutical Co., Ltd. Agent antiseptique contenant de la meglumine ou un sel correspondant
CN107789323B (zh) * 2016-08-31 2021-05-07 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
CN107789324B (zh) * 2016-08-31 2021-05-25 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺及其制备方法
KR102323255B1 (ko) * 2017-02-15 2021-11-08 다이호야쿠힌고교 가부시키가이샤 의약 조성물

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998A (en) 1849-01-02 Improvement in combined plows
US436A (en) 1837-10-23 Brick mold used in brick-pressing machines
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
CA2290712C (fr) 1995-09-22 2003-09-09 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives de l'acide pyridone-carboxylique ou leurs sels et agent antibacterien les contenant comme ingredient actif
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
MXPA01010247A (es) 1999-04-15 2002-03-27 Lilly Co Eli Composiciones antifungosas de pseudomicina y metodos para su uso.
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
CA2441744C (fr) * 2001-03-20 2011-07-12 Cydex, Inc. Preparation contenant du propofol et de la cyclodextrine d'ether sulfoalkylique
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
DE60213841T2 (de) 2001-11-05 2007-02-15 Merck Patent Gmbh Hydrazono-malonitrile
AU2002361493A1 (en) 2001-12-13 2003-06-23 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070129328A1 (en) 2004-01-30 2007-06-07 BOETTNER Wayne Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
CN1244582C (zh) 2004-04-21 2006-03-08 中国医学科学院医药生物技术研究所 喹诺酮羧酸类化合物及其制备方法和医药用途
EP1764102A4 (fr) 2004-07-02 2010-08-25 Daiichi Seiyaku Co Composition médicinale contenant de la quinolone
EP2816033A1 (fr) 2004-07-30 2014-12-24 Abbvie Inc. Préparation de substances antibactériennes à base d'acide pyridonecarboxylique
ES2901955T3 (es) 2004-10-08 2022-03-24 Abbvie Inc Sal meglumínica y formas cristalinas de la misma de un farmaco (delafloxacina)
EP2286800A1 (fr) * 2005-04-11 2011-02-23 Abbott Laboratories Composition pharmaceutiques présentant des profiles de dissolution améliorés pour des medicaments peu solubles
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070238720A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CA2611917A1 (fr) 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Produit d'injection
US7795207B2 (en) 2005-11-21 2010-09-14 Harald Labischinski Lipopeptide compositions
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
EP1897542A1 (fr) 2006-09-07 2008-03-12 Sanofi-Aventis Composition aqueuse comprenant un agent antitumoral
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
EP2074111A2 (fr) 2006-10-06 2009-07-01 Bausch & Lomb Incorporated Acides carboxyliques de quinolone, dérivés de ceux-ci et leurs procédés de préparation et d'utilisation
WO2008085913A1 (fr) 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Procédés pour traiter, prévenir, ou réduire le risque d'infections ophtalmiques, otiques, et nasales
US7632944B2 (en) 2007-01-24 2009-12-15 Bausch & Lomb Incorporated Quinolone carboxylic acids, derivatives thereof, and methods of making and using same
KR20080075349A (ko) 2007-02-12 2008-08-18 동진파마 주식회사 수용성 실리마린 조성물과 그 제조방법
TWI362386B (en) 2007-03-30 2012-04-21 Daiichi Sankyo Co Ltd A production method for the qunolon-carboxylic acid derivative
EP2373166A4 (fr) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc Compositions antimicrobiennes
JP6129751B2 (ja) 2011-02-25 2017-05-17 シンセス・ゲーエムベーハーＳｙｎｔｈｅｓ ＧｍｂＨ 骨形成促進インプラント及び骨成長を誘導する方法

Also Published As

Publication number Publication date
MY194407A (en) 2022-11-30
IL212781A (en) 2016-12-29
CR20110320A (es) 2011-10-18
HK1213821A1 (zh) 2016-07-15
JP2012508757A (ja) 2012-04-12
WO2010056872A2 (fr) 2010-05-20
IL212781A0 (en) 2011-07-31
CA2743419A1 (fr) 2010-05-20
BRPI0921705A2 (pt) 2015-08-25
JP2015091856A (ja) 2015-05-14
US20120065186A1 (en) 2012-03-15
US20220265636A1 (en) 2022-08-25
CN104958296B (zh) 2017-12-01
MY161597A (en) 2017-04-28
US20160235736A1 (en) 2016-08-18
NI201100097A (es) 2011-09-08
EA201170689A1 (ru) 2013-10-30
CN102215690B (zh) 2015-07-01
EP2373166A4 (fr) 2014-11-05
UA102709C2 (uk) 2013-08-12
US12138257B2 (en) 2024-11-12
CN103705942A (zh) 2014-04-09
PE20160116A1 (es) 2016-03-09
PE20120029A1 (es) 2012-02-13
JP2017031164A (ja) 2017-02-09
JP6063123B2 (ja) 2017-01-18
NZ593345A (en) 2013-04-26
KR101767689B1 (ko) 2017-08-11
BRPI0921705B8 (pt) 2021-05-25
AU2009314072C1 (en) 2016-11-10
AU2009314072A1 (en) 2011-06-30
CN103705942B (zh) 2016-08-24
KR20120008020A (ko) 2012-01-25
MX2011005117A (es) 2011-10-21
SV2011003907A (es) 2011-12-06
ECSP11011119A (es) 2011-11-30
CN102215690A (zh) 2011-10-12
US20200022971A1 (en) 2020-01-23
WO2010056872A3 (fr) 2010-07-29
BR122020021551B1 (pt) 2021-09-21
JP6407221B2 (ja) 2018-10-17
CN104958296A (zh) 2015-10-07
EP2373166A2 (fr) 2011-10-12
ZA201104108B (en) 2012-09-26
AU2009314072B2 (en) 2016-05-19
CO6382082A2 (es) 2012-02-15
MY188453A (en) 2021-12-09
EA025637B1 (ru) 2017-01-30
US20240307368A1 (en) 2024-09-19
CA2743419C (fr) 2017-02-14
BRPI0921705B1 (pt) 2021-01-19

Similar Documents

Publication Publication Date Title
MA32931B1 (fr) Compositions antimicrobiennes
MA30406B1 (fr) Nouveaux composes
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
TW200806299A (en) Treatment of pain
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
IN2012DN01233A (fr)
EA200970047A1 (ru) Водные суспензии тмс278
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
MA34002B1 (fr) Thérapie antivirale
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
EP2638905A3 (fr) Traitement de biofilm
WO2010057101A3 (fr) Composés utiles en tant qu’inhibiteurs de vih
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
MX2011012614A (es) Compuestos de quetolida que tienen actividad antimicrobiana.
WO2006078424A3 (fr) Compositions polyherbales et technique de traitement d'infections virales
TW200639159A (en) Treatment of pain
TW200734334A (en) Treatment of substance abuse
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
JO2820B1 (en) Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases
EA200900552A1 (ru) Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами